The extracellular matrix (ECM) is a complex meshwork of insoluble fibrillar proteins and signaling factors interacting together to provide architectural and instructional cues to the surrounding cells.
INTRODUCTION
The extracellular matrix (ECM), a complex and dynamic meshwork of cross-linked proteins, is a fundamental component of multicellular organisms 1 . The ECM provides architectural, mechanical, and biochemical signals interpreted by cell-surface receptors, and orchestrates cellular processes such as adhesion, migration, proliferation, survival, and differentiation 2, 3 . Alterations in the composition and organization of the ECM cause or accompany the development of diseases including fibroses, cardiovascular diseases, and cancers [4] [5] [6] .
Because of its complexity and insolubility, the ECM has been difficult to analyze biochemically and, until recently, it was not possible to obtain a detailed understanding of its composition 7 . We have previously developed a proteomic pipeline to characterize the composition of in vivo ECMs and have
shown that any given tissue or tumor includes well over 100 ECM and ECM-associated proteins and that characteristic differences can be detected between different tissues or tumors [8] [9] [10] . One critical step in this proteomic approach was the development of a method to enrich ECM proteins from tissues and tumors. To do so, we and others devised decellularization methods that deplete intracellular proteins and permit the enrichment of ECM proteins 8, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . A second critical step of the approach was the identification and annotation of the ECM components, or 'matrisome', in large proteomic datasets. To this end, we devised a computational approach and defined the in silico matrisome as the ensemble of genes encoding core ECM proteins (ECM glycoproteins, collagens, and proteoglycans) and ECMassociated proteins (these are proteins structurally resembling ECM proteins, ECM remodeling enzymes and secreted factors including growth factors) 8, 21 .
As the details of the methods applied in the various analyses of ECM proteins using massspectrometry-based proteomics in our laboratories and others vary somewhat, we have now explored the impact of variations in the protocols. We provide here updated protocols for 1) digestion of ECM proteins into peptides, 2) analysis of ECM peptides by mass spectrometry, and 3) interpretation of mass spectrometric data. We illustrate the protocols with results obtained on the ECM from two sets of tissues that differ significantly in their ECM content and cellularity: human triple-negative breast cancer samples and adjacent breast tissue, and omental metastases from high-grade serous ovarian cancer (HGSOC) and normal omentum ( Figure 1A ). The optimized protocols presented here make the 4 comprehensive characterization of the composition of the ECM accessible to a broad range of scientists and should help enhance the identification of disease biomarkers and novel therapeutic targets. Table S1A ).
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MATERIALS AND METHODS
Samples
Masson's trichrome staining was performed according to standard procedures to evaluate the ECM content and cellularity of all four tissue types.
Enrichment for ECM components
ECM proteins were enriched from frozen whole tissue or tumor sections (20 x 30 μm sections, approximately 40-50 mg of tissue) as previously described 15 . In brief, tissue sections were resuspended in the cytosolic ("C") buffer of the CNMCS compartmental protein extraction kit (Millipore) and disrupted by vortexing. The samples were then incubated in a series of buffers to remove sequentially nuclear proteins (buffer "N"), membrane proteins (buffer "M"), and cytoskeletal proteins (buffer "CS"), according to the manufacturer's instructions and our previous protocol 15 . The remaining insoluble pellet is enriched for ECM proteins. Note that the subsequent steps can also be conducted on ECMenriched samples prepared according to other methods [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
ECM protein solubilization
ECM-enriched samples were solubilised in 8M urea, 20mM HEPES containing Na 3 VO 4 (100mM), NaF (0.5M), β-Glycerol Phosphate (1M), Na 2 H 2 P 2 O 7 (0.25M). Samples were vortexed for 30 seconds and held on ice prior to sonication at 50 % intensity, 3 times for 15 seconds, on ice. These resuspended and partially solubilized ECM-enriched samples were either directly digested into peptides as described below ("crude" ECM samples), or were centrifuged at 20,000 g for 10 min at 5 o C, and the supernatant recovered to protein low-bind tubes. This fraction will further be referred to as the urea-soluble fraction. Protein concentration of the urea-soluble fraction was estimated using BCA assay and 80 μg of protein was digested into peptides as described below. The post-centrifugation urea-insoluble pellet was resuspended in 2M urea and proteins were digested as described below.
ECM protein digestion into peptides
Disulphide bonds were reduced by adding 5mM dithiothreitol to the samples for a 1-hour incubation under agitation at room temperature. 
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Equal volumes of each sample, corresponding to approximately 100ng of material, were initially analyzed via LC-MS/MS, and the total numbers of peptides identified and the sum of the intensities of the precursor ions was used as a normalization metric to determine equivalent peptide amounts.
Peptides were separated by reversed-phase HPLC using an EASY-nLC1000 (Thermo Scientific) using a pre-column (made in house, 6 cm of 10 µm C18) and a self-pack 5 µm tip analytical column (12 cm of 5 µm C18, New Objective) over a 140-minute gradient before nanoelectrospray using a QExactive mass spectrometer (Thermo). Solvent A was 0.1% formic acid and solvent B was 80% MeCN/0.1% 
Off-line fractionation of peptides by reversed-phase chromatography at high pH
Equivalent peptide amounts were fractionated via high-pH reversed-phase HPLC. Peptides were resuspended in 50uL buffer A (10mM NH 4 HCO 3 , pH8) and separated on a 4.6mm x 250 mm 300Extend-C18, 5um column (Agilent) using an 80-minute gradient from 1% to 100% buffer B (90% MeCN, 10mM NH 4 HCO 3 , pH8) at a flow rate of 1ml/min. Fractions were collected over 75 minutes at 1-minute intervals beginning at 5 minutes after the start of the gradient. The fractions were concatenated into 15 fractions non-contiguously (1+16+31+46+61, 2+17+32+47+62, etc.) 22 . The fractions were brought to near dryness in a speed-vac (Thermo Scientific). Each fraction was resuspended in 80uL 0.1% formic acid and 4uL was analyzed via LC-MS/MS as described above using the same 140-minute gradient.
Protein identification
Raw mass spectral data files (.raw) were searched using Proteome Discoverer (Thermo Scientific) and The raw mass spectrometry data have been deposited to the ProteomeXchange 23 via the PRIDE partner repository 24 with the dataset identifier: PXD005554.
RESULTS
Optimization of methods to solubilize and digest ECM proteins
We initially devised a method that consisted of enrichment of tissue samples for ECM proteins, partial solubilization in 8M urea and digestion of this "crude" ECM extract into peptides. Using this protocol, the most abundant proteins identified were fibrillar collagens 8 . We hypothesized that the abundance of fibrillar collagens could prevent the identification of other ECM or ECM-associated proteins present in lower abundance. To test this, we compared the original method with a method consisting of digesting only the urea-soluble fraction of ECM-enriched samples ( Figure 1B This might be explained by the low content of fibrillar ECM in this tissue ( Figure 1A) .
We next sought to analyze the composition of the urea-insoluble protein fraction (Supplementary Figure S1A and Supplementary Table S1B ) and observed that only four proteins were detected solely in the pellet and not in either urea-soluble or crude ECM preparations (namely, AMBP and LMAN1L, which is in fact a transmembrane protein, in TNBC-adjacent breast tissue and COL6A5 and MFAP2 in TNBC samples) (Supplementary Figure S1B and Supplementary Table S1B ). However, the total number of matrisome proteins detected in the pellet was less than either the crude or urea-soluble preparations. It is possible that with more extensive analysis, including peptide-fractionation (see below), these proteins would also be detected in the urea-soluble and/or crude ECM preparations.
Therefore, in general, both crude and urea-soluble extractions result in similar numbers of ECM proteins detected, although one method may be superior to the other depending on the tissue and in particular, depending on the collagen content of the tissue.
Optimization of methods to fractionate ECM-protein-derived peptides
We have previously reported that off-line fractionation of peptide mixtures by off-gel electrophoresis increased by a factor of 3 the number of matrisome peptides confidently identified, which resulted in the identification of twice as many core ECM components and over 10 times the number of matrisomeassociated proteins 8 . Off-gel electrophoresis is a lengthy process, and is now being replaced in proteomic pipelines by fractionation using high-pH liquid chromatography (also termed basic-reversedphase or bRP-LC), orthogonal to the LC separation in-line with the tandem mass spectrometry. We sought to determine whether fractionation by bRP-LC was beneficial to identify otherwise undetected ECM proteins from both urea-soluble and crude ECM preparations. Independent of the tissue type or the method employed to digest ECM-enriched samples into peptides, fractionation prior to LC-MS/MS resulted in the identification of a greater number of spectra and proteins ( Figure 3 and Supplementary   Table S1D ). In the case of omental samples, the urea-soluble preparation, when coupled with bRP-LC fractionation, consistently resulted in higher numbers of ECM proteins detected when compared to fractionated crude preparations ( Figure 3A) . This is presumably a consequence of the reduced amount of collagens in the urea-soluble fraction (Supplementary Table S1D ). Furthermore, peptide fractionation was particularly beneficial to identify lower-abundance matrisome-associated proteins such as ECM-affiliated proteins and ECM regulators (including ECM cross-linking enzymes or proteases) ( Figure 3B and 3C and Supplementary Table S1D ).
Importance of allowing for proline hydoxylations for in silico protein identification
Peptide and subsequent protein identification from tandem mass spectrometry data rely on the comparison of experimental spectral mass values with databases containing theoretical spectral data. It is important that search algorithms include post-translational modifications (PTMs) that alter the mass of amino acids. Hydroxylation of prolines and lysines are obligate PTMs of triple-helical collagens (prolines represent 17% of amino acids in collagen I) and other ECM proteins [25] [26] [27] . However, these PTMs are not routinely included when interrogating databases for protein identification because they increase the search time. To examine the significance of including the dynamic modifications of lysine and proline hydoxylation, we selected a dataset and conducted a database search in four different ways: without allowing for lysine or proline hydroxylation; allowing only lysine hydroxylation;
allowing only proline hydroxylation, or allowing both lysine and proline hydroxylation. Allowing for proline hydroxylations (and to a lesser extent for lysine hydroxylations) led to a significant increase of the number of identified spectra of matrisome proteins by factor of 2 ( Figure 4A , left panels), as also previously reported by Barallobre-Barreiro and collaborators 28 , and thus to a more accurate estimation of the abundance of matrisome proteins ( Figure 4B , left panel). Allowing these PTMs also allowed the identification of several additional ECM proteins ( Figure 4C , left panel, and Supplementary Table S1E and 1F). Importantly, allowing for these two PTMs was equally beneficial to the analysis of ureasoluble and crude ECM extracts. Of note, these two PTMs, did not increase significantly the number of spectra or unique peptides of non-matrisome proteins ( Figure 4A -C, right panels). Therefore, allowing for proline and lysine hydroxlations is beneficial specifically for the detection of ECM proteins and we recommend they be included.
Scripts to annotate matrisome proteins and calculate mass-spectrometric metrics
In order to facilitate the annotations of matrisome proteins in large datasets, we developed a script called "Matrisome Annotator". Providing that a dataset contains Entrez or HUGO gene symbols for each entry, the script will return an output file in which each entry will be annotated as being part of the matrisome or not, and will be tagged with matrisome division (core matrisome vs. matrisome- [Note to the editor and reviewers: the "Analytical Tools" section of the website is password protected during the evaluation of the manuscript and will be made publicly available upon acceptance of the manuscript. To access the pages, log in to the website using the login button located on the upper right corner of the website with the following credentials: login: reviewer; password: matrisome. The
Analytical tools" section will appear on the left menu with two sub-pages "Matrisome Annotator" and "Matrisome Analyzer". We have provided detailed description of the scripts and user manual on the dedicated web pages].
DISCUSSION
We provide here a detailed description of mass-spectrometry-based methods allowing in-depth and comprehensive characterization of the composition of ECM of normal and diseased tissues. The major advantage of these methods is that each step, from the solubilization of ECM proteins to the interpretation of mass spectrometric data, has been optimized to take into account biochemical characteristics of ECM and ECM-associated proteins. For example, we recommend allowing for proline and lysine hydroxylation when searching databases, as this significantly increases ECM protein detection and identification. The preferred method to solubilize ECM-enriched protein samples for digestion to peptides depends on the tissue and its ECM content and, in some cases, restricting the analysis to urea-soluble ECM proteins, permits detection of additional proteins. This is because significant proportions of the collagens remain insoluble. Few proteins are missed by ignoring the ureainsoluble fraction, although of course, the relative amounts of proteins detected are altered, which compromises semi-quantitative conclusions. Furthermore, inclusion of a pre-fractionation step by bRP-LC chromatography provides an alternative means, allowing detection of additional proteins. It is worth noting that high pH reversed-phase peptide fractionation can be achieved using commercially available spin columns requiring only a bench centrifuge. In addition, any number of fractions can be generated depending on the complexity of the samples and the desired coverage.
Although not discussed in the manuscript, these methods can be coupled to label-based quantitative proteomics 29 , which allows quantification of the abundance of proteins and peptides in different samples, and also allows multiplexing, thus reducing mass-spectrometer time.
CONCLUSION
Alterations in the composition and organization of the ECM cause or accompany the development of diseases such as fibrosis, cardio-vascular diseases, musculo-skeletal diseases, and cancers.
The application of the proposed methods to profile the composition of the ECM of, for example, pairs of normal vs. diseased tissues, treated vs. untreated tissues, or poorly vs. highly metastatic tumors, or cell or organoid cultures can lead to the identification of novel ECM proteins that could serve as prognostic or diagnostic biomarkers or novel therapeutic targets.
